Hypertension
Conditions
Brief summary
The purpose of this study is to evaluate the splenic activation in hypertensive patients, as compared to normotensives, using FDG-PET/CT imaging. Moreover, the investigators will investigate whether the splenic metabolic activity relates to the expression of circulating inflammatory proteins (high-sensitivity C-reactive protein \[hsCRP\]), interleukin-1b (IL-1b), tumor necrosis factor-a (TNF-a) or to immune profiles of activated T cells.
Interventions
OTHERPET/CT scan
PET/CT scan
Sponsors
Neuromed IRCCS
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
30 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* absence of prior cancer diagnosis or remission from cancer at the time of FDG-PET/CT imaging (from at least 6 months) * age ≥ 30 and ≤ 85 years * absence of acute cardio/cerebrovascular disease (myocardial infarction, stroke, transient ischemic attack, revascularization) * absence of acute or chronic inflammatory or autoimmune disease * diagnosis of presence/absence of hypertension, on the basis of documented medical history
Exclusion criteria
* diabetes * atrial fibrillation * use of anti-inflammatory drugs in the week preceding the FDG-PET/CT imaging * chronic use of anti-inflammatory drugs
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Splenic metabolic activity | At enrollment | 18FDG uptake in splenic tissue |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Circulating pro-inflammatory markers | At enrollment | Serum levels of pro-inflammatory cytokines |
Countries
Italy
Contacts
Primary ContactGiuseppe Lembo, MD in Cardiology
Outcome results
None listed